News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Norbert Kraut: A must-read Precision Oncology: 2023 in Review
Photo taken from Norbert Kraut/X
Dec 24, 2023, 18:34

Norbert Kraut: A must-read Precision Oncology: 2023 in Review

Norbert Kraut, Global Head of Cancer Research, Boehringer Ingelheim, shared on X/Twitter:

“2023 has been a year with major advances in precision oncology. A must-read in Cancer Discovery. Precision Oncology: 2023 in Review.”

Source: Norbert Kraut/X

Boehringer Ingelheim cancer Cancer Discovery Norbert Kraut OncoDaily Oncology Precision Oncology
Special Coverage
Blog
Feb 21, 2025, 10:55
Mourning the untimely passing of Giovanni Scambia - a visionary leader in European gynecologic oncology
Blog
Feb 21, 2025, 10:45
Saurabh Zanwar: Clonal plasma cell proportion in the S-phase in multiple myeloma
Blog
Feb 21, 2025, 10:37
Cihangir Akyol: A comprehensive review on colorectal ESD outcomes by Lumir Kunovsky
Celebrities
Feb 21, 2025, 10:28
In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer
Science
Feb 21, 2025, 10:07
Elai Davicioni: Predicting Dose-Response to Prostate Cancer Radiotherapy
Blog
Feb 21, 2025, 10:00
Alexios Matikas: Adjuvant endocrine treatment strategies for non-metastatic breast cancer
Blog
Feb 21, 2025, 09:58
Miriam Mutebi: February - a whirlwind of learning, collaboration, and action
Blog
Feb 21, 2025, 09:54
The publication of the European Commission Work Programme for 2025 - ESMO
Blog
Feb 21, 2025, 09:45
Michelle Kirschner: New programming at the Cancer Survivorship Provider Network
Science
Feb 21, 2025, 09:39
M. Bilal Abid: Excited to present at the UT San Antonio MD Anderson Cancer Center
Blog
Feb 21, 2025, 09:35
UICC is seeking an Executive Director to lead the ATOM Coalition in Geneva
Blog
Feb 21, 2025, 09:18
Belén Garijo: A very important evolution of Merck Group's Executive Board